ARYA Sciences Acquisition IV priced its IPO of 13 million Class A ordinary shares at $10 per share.
Shares start trading today on the Nasdaq under ARYD.
Arya III earlier this month announced a proposed business combination with Nautilus Biotechnology at a $1.3 billion valuation.
The new SPAC said it intends to focus on the healthcare industry in the United States and other developed countries. Read more.
